LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and artificial intelligence solutions for Latin America, has announced a new collaboration through its Venezuelan subsidiary, LATAMEDAI VE, with DROGUERIAS LALA C.A. The agreement aims to develop artificial intelligence-supported and automated software tools designed to enhance pharmaceutical and laboratory operations.
The partnership will focus on designing, developing, testing, and evaluating customized technology to support workflows related to pharmaceutical research, laboratory testing, quality control, documentation, operational coordination, and data analysis. The proposed technology is expected to include features such as workflow automation, testing coordination, document management, data review, quality-control support, and predictive analytics to help identify potential inconsistencies or operational issues early.
According to the announcement, the initial phase will involve identifying specific workflows, defining technical and operational requirements, and establishing a phased development and testing process. The parties also intend to implement confidentiality, information-security, data-management, and access-control procedures to safeguard sensitive information.
The technology is designed as a decision-support and workflow-management resource, not as a replacement for professional judgment. It will not independently approve pharmaceutical formulas, laboratory results, medical products, or regulatory submissions. All final determinations will remain the responsibility of qualified professionals and regulatory authorities.
Dr. Kevin Rodan Levy, CEO of LataMed AI, stated, "This agreement represents an opportunity to apply our artificial intelligence and automation capabilities within complex pharmaceutical and laboratory environments. Our objective is to work with DROGUERIAS LALA C.A. to develop responsible technology that supports data analysis, documentation, testing coordination, quality-control processes, and other operational requirements while preserving appropriate professional oversight."
This collaboration marks a strategic expansion for LataMed AI beyond its patient-facing telemedicine services into enterprise pharmaceutical and laboratory applications. The initiative aligns with the company's broader strategy of developing digital infrastructure and AI-supported tools for healthcare providers, pharmacies, laboratories, and other ecosystem participants.
If successful, the technology could potentially be adapted for other organizations in Venezuela and Latin America, subject to separate agreements, successful development, regulatory compliance, and operational readiness. The parties will also evaluate ownership, licensing, and intellectual-property protections for any developed technology.
The agreement establishes a framework for collaboration but does not guarantee specific implementation schedules, cost reductions, revenue, or expansion. LataMed AI will provide updates as development progresses.
For more information, visit LataMed AI's website or review the company's filings with the SEC at www.sec.gov.
